Skip to content
value.today
Processa Pharmaceuticals, Inc. logo

Processa Pharmaceuticals, Inc.

PCSA
$5 Mmarket cap on Oct 30, 2026-41.2% since Jan 2024
Compare
World rank
#26,844
Revenue
β€”
For year ending December-2025
Net income
$-14 M
SEC filing
Employees
β€”

Processa Pharmaceuticals, Inc. in brief

Processa Pharmaceuticals, Inc. is a listed company in the Biotechnology industry, based in Maryland, USA. Its market value was $5 M on 30 October 2026, which makes it the 26,844th largest listed company in the world and the 4,399th largest in the USA on this site. George K. Ng is its chief executive. Its shares trade under the symbol PCSA (Nasdaq).

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

About Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc. was incorporated under the laws of the State of Delaware on March 29, 2011. Our principal executive office is located at 601 21st Street, Suite 300 Vero Beach, FL 32960. Our telephone number is (772) 453-2899.

We make available free of charge on or through our Internet website (http://www.processapharmaceuticals.com) our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and, if applicable, amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (SEC), as well as our Code of Ethics and Code of Conduct. The SEC also maintains a website which provides online access to reports and other information regarding registrants that file electronically with the SEC at: www.sec.gov.

From the company's annual report filed with the US SEC: read the report

Processa Pharmaceuticals, Inc. timeline

2 events, 2011–2017
  1. 2011
  2. β€’
    Β· approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2017
  4. ✎
    Renamed Processa Pharmaceuticals, Inc.
    Formerly Heatwurx, Inc..

Events of Processa Pharmaceuticals, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$20 M$41 M$61 M$81 M2023202420252026

World rank over time

β–Ό down 2,842 places since 2022
2022-01-07: #23998#23,99820222022-12-25: #29489#29,48920222023-07-30: #31240#31,24020232024-01-05: #31390#31,39020242026-03-08: #13053#13,05320262026-08-01: #23191#23,19120262026-10-14: #26973#26,97320262026-10-30: #26840#26,8402026

Rank in USA: #4,629 (Jan 2022) Β· #5,304 (Dec 2022) Β· #5,392 (Jul 2023) Β· #4,534 (Jan 2024) Β· #2,429 (Mar 2026) Β· #4,073 (Aug 2026) Β· #4,358 (Oct 2026) Β· #4,397 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
β€”
Price / book
0.9Γ—
Free cash flow yield
-212.7%
Net margin
β€”
Operating margin
β€”
Return on equity
-243.0%
Liabilities / assets
28.7%
Revenue growth
0.0%
R&D / revenue
27.3%

Financial history

USD Β· fiscal years Β· source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue β€”, net income $-4Mβ€”FY18Fiscal year ending Dec 2019: revenue β€”, net income $-3Mβ€”FY19Fiscal year ending Dec 2020: revenue β€”, net income $-14Mβ€”FY20Fiscal year ending Dec 2021: revenue β€”, net income $-11Mβ€”FY21Fiscal year ending Dec 2022: revenue β€”, net income $-27Mβ€”FY22Fiscal year ending Dec 2023: revenue β€”, net income $-11Mβ€”FY23Fiscal year ending Dec 2024: revenue β€”, net income $-12Mβ€”FY24Fiscal year ending Dec 2025: revenue β€”, net income $-14Mβ€”FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025β€”β€”$-14M$-14Mβ€”
Dec 2024β€”β€”$-12M$-12Mβ€”
Dec 2023β€”β€”$-11M$-11Mβ€”
Dec 2022β€”β€”$-28M$-27Mβ€”
Dec 2021β€”β€”$-12M$-11Mβ€”
Dec 2020β€”β€”$-15M$-14Mβ€”
Dec 2019β€”β€”$-4M$-3Mβ€”
Dec 2018β€”β€”$-5M$-4Mβ€”

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-11Mβ€”β€”$-10.36β€”
Dec 2024$-11M$0M$-11M$-96.78β€”
Dec 2023$-8M$0M$-8M$-8.48β€”
Dec 2022$-10Mβ€”β€”$-34.05β€”
Dec 2021$-9Mβ€”β€”$-0.75β€”
Dec 2020$-3Mβ€”β€”$-2.54β€”
Dec 2019$-3Mβ€”β€”$-0.70β€”
Dec 2018$-4Mβ€”β€”$-0.71β€”

Quarterly results

USD Β· three months to Β· source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue β€”, net income $-3Mβ€”Dec ’24Three months to Mar 2025: revenue β€”, net income $-3Mβ€”Mar ’25Three months to Jun 2025: revenue β€”, net income $-4Mβ€”Jun ’25Three months to Sep 2025: revenue β€”, net income $-3Mβ€”Sep ’25Three months to Dec 2025 (from the annual report): revenue β€”, net income $-3Mβ€”Dec ’25Three months to Mar 2026: revenue β€”, net income $-3Mβ€”Mar ’26Three months to Jun 2026: revenue β€”, net income $-3Mβ€”Jun ’26Three months to Sep 2026: revenue β€”, net income $-183Mβ€”Sep ’26

Latest quarter to Sep 2026: revenue β€”, net income $-183M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

Official filings of Processa Pharmaceuticals, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
β€”
Operating income
$-14 M
Net income
$-14 M

For year ending December-2025 Β· source: SEC filing

Balance sheet

Total assets
$8 M
Total liabilities
$2 M
Total equity
$6 M

As of December-2025

Top 18 institutional investors in Processa Pharmaceuticals, Inc.#

As of Sep 30, 2026
18 institutions held 3.7 M shares (more than all shares outstanding: lent and sub-advised shares are reported by more than one filer) on Sep 30, 2026. Filings read through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 18 largest institutional investors in Processa Pharmaceuticals, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Adage Capital Partners GP, L.L.C.3,275,493New117.26%$5 MNov 16, 2026
2Soleus Capital Management, L.P.160,943New5.76%$0 MNov 16, 2026
3Connective Capital Management, LLC85,2740 (0.00%)3.05%$0 MNov 16, 2026
4Citadel Advisors LLC58,629+37,323 (+175.18%)2.10%$0 MNov 16, 2026
5Geode Capital Management, LLC31,252+9,162 (+41.48%)1.12%$0 MNov 6, 2026
6Seven Fleet Capital Management LP18,300New0.66%$0 MNov 16, 2026
7Janus Henderson Group Ltd.18,016β€”0.65%$0 MNov 16, 2026
8Jane Street Group, LLC13,571+307 (+2.31%)0.49%$0 MNov 12, 2026
9Vanguard Capital Management LLC12,7290 (0.00%)0.46%$0 MNov 13, 2026
10Vanguard Fiduciary Trust Co10,8570 (0.00%)0.39%$0 MNov 13, 2026
11UBS Group AG6,774-1,020 (-13.09%)0.24%$0 MNov 10, 2026
12Millennium Management LLC1,875New0.07%$0 MNov 16, 2026
13Tower Research Capital LLC (TRC)419-2,080 (-83.23%)0.01%$0 MNov 16, 2026
14Robinhood Markets, Inc.59β€”0.00%$0 MNov 18, 2026
15Jpmorgan Chase & Co18New0.00%$0 MNov 12, 2026
16Jones Financial Companies Lllp70 (0.00%)0.00%$0 MNov 13, 2026
17FMR LLC6New0.00%$0 MNov 10, 2026
18Barclays PLC3New0.00%$0 MNov 6, 2026

Mutual funds holding Processa Pharmaceuticals, Inc.#

4 funds hold shares worth $0 M (about 1.1% of the company). Since their previous reports 0 added shares and 1 sold.
Mutual funds holding Processa Pharmaceuticals, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
πŸ‡ΊπŸ‡Έ Fidelity Extended Market Index FundFidelity Management & Research Company LLC14,221$0 M0.51%<0.01%βˆ’3.0%May 31, 2026
πŸ‡ΊπŸ‡Έ Vanguard Extended Market Index FundThe Vanguard Group, Inc.12,729$0 M0.46%<0.01%no changeJun 30, 2026
πŸ‡ΊπŸ‡Έ Fidelity Series Total Market Index FundFidelity Management & Research Company LLC2,088$0 M0.07%<0.01%no changeMay 31, 2026
πŸ‡ΊπŸ‡Έ Fidelity Total Market Index FundFidelity Management & Research Company LLC969$0 M0.03%<0.01%no changeMay 31, 2026

As of Jun 30, 2026

Insider trading at Processa Pharmaceuticals, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$203 K
41 purchases, 9 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$203 K
open market only
Insiders on file
15
since
$214 K$0Jan 2024: bought $54 K (3 trades), sold $0 (0 trades)Jan 24Feb 2024: bought $106 K (3 trades), sold $0 (0 trades)FebJan 2025: bought $214 K (4 trades), sold $0 (0 trades)Jan 25Mar 2026: bought $43 K (9 trades), sold $0 (0 trades)MarApr 2026: bought $60 K (12 trades), sold $0 (0 trades)AprMay 2026: bought $49 K (10 trades), sold $0 (0 trades)MayJun 2026: bought $45 K (9 trades), sold $0 (0 trades)JunJul 2026: bought $6 K (1 trades), sold $0 (0 trades)Jul
Bought (open market)Sold (open market)Hover a month for the totals
Processa Pharmaceuticals, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed George K. NgChief Executive Officer, DirectorOption exercise+1,600β€”β€”17,092Form 4
filed George K. NgChief Executive Officer, DirectorBuy+3,057$1.930$6 K15,492Form 4
filed David YoungPres. Research & Development, DirectorBuy+2,531$1.930$5 K21,729Form 4
filed Patrick LinChief Business - Strategy OffBuy+2,106$1.930$4 K13,113Form 4
filed Russell SkibstedChief Financial OfficerBuy+3,277$1.930$6 K16,689Form 4
filed Wendy GuyChief Administrative OfficerBuy+2,436$1.930$5 K14,394Form 4
filed Justin W. YorkeDirectorOption exercise+203β€”β€”353Form 4
filed James R. NealDirectorOption exercise+203β€”β€”1,021Form 4

Markets and events: Processa Pharmaceuticals, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
26,138
1.0% of shares Β· 1 days to cover
Shares sold short, last 24 reportsAll stocks β†’

Trading halts

  • 2026-10-09 14:28 UTC, code LUDP, resumed 14:33 UTC
  • 2025-12-17 20:51 UTC, code LUDP, resumed 21:00 UTC
  • 2025-12-17 20:09 UTC, code LUDP, resumed 20:14 UTC
  • 2025-12-17 17:50 UTC, code LUDP, resumed 17:55 UTC
  • 2025-12-17 16:42 UTC, code LUDP, resumed 16:47 UTC

Fails to deliver

  • : 100 shares at $1.89
  • : 100 shares at $1.85
  • : 2,778 shares at $1.82
  • : 100 shares at $1.80
  • : 100 shares at $1.81

Processa Pharmaceuticals, Inc. scorecard#

Passes 3 of the 10 checks that could be worked out: strongest in valuation (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 3
  • Growth1 of 2
  • Profitability0 of 3
  • Financial health1 of 2
  • Shareholder returnsnot known

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Processa Pharmaceuticals, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Processa Pharmaceuticals, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenueβ€”β€”β€”00β€”β€”β€”β€”0.0
Gross profitβ€”β€”β€”β€”β€”β€”β€”β€”β€”0.0
Research and development7.87.35.8116.93.22.33.11.0r1.5r
Selling, general and administrativeβ€”β€”β€”β€”β€”β€”β€”1.40.80.1
General and administrative6.24.85.78.84.73.31.61.4β€”β€”
Operating expensesβ€”β€”β€”β€”β€”β€”β€”β€”1.81.9r
Operating incomeβˆ’14βˆ’12βˆ’11βˆ’28βˆ’12βˆ’15βˆ’3.9βˆ’4.5βˆ’1.8βˆ’1.9
Interest and finance income0.10.20.30.10.0r0.00.00.00.00.0
Interest expense and finance costsβ€”β€”β€”β€”0.00.30.00.20.10.2
Income before taxβˆ’14βˆ’12βˆ’11βˆ’27βˆ’12βˆ’15βˆ’4.0βˆ’4.7βˆ’1.9βˆ’0.3
Income taxβ€”β€”β€”β€”βˆ’0.5βˆ’1.0βˆ’0.6βˆ’0.90.3β€”
Income from continuing operationsβ€”β€”β€”β€”β€”β€”β€”β€”βˆ’1.9βˆ’1.9r
Income from discontinued operationsβ€”β€”β€”β€”β€”β€”β€”β€”β€”0.0
Net income attributable to shareholdersβˆ’14βˆ’12βˆ’11βˆ’27βˆ’11βˆ’14βˆ’3.4βˆ’3.8βˆ’1.9βˆ’1.9r
Earnings per share, basic-10.36-96.78r-8.48-34.05r-0.75-2.54-0.70-0.71r-0.06-0.07r
Earnings per share, diluted-10.36-96.78r-8.48-34.05-0.75-2.54-0.70-0.71r-0.06-0.07r
Shares, weighted average (basic)1.30.1r1.30.8r15β€”β€”β€”3329
Shares, weighted average (diluted)1.30.1r1.30.8157.55.5r5.3r3329r
Balance sheet
Cash and cash equivalents5.5r1.24.76.516150.71.72.81.1r
Other current assets0.1r0.7r0.91.91.80.60.30.3β€”β€”
Current assets5.7r1.9r5.68.418161.02.03.02.3r
Property, plant and equipment0.0r0.00.0β€”β€”0.00.00.00.00.0
Right-of-use (leased) assetsβ€”0.10.10.20.10.20.2β€”β€”β€”
Other intangible assetsβ€”β€”β€”β€”8.18.89.610β€”β€”
Non-current assetsβ€”1.3β€”0.28.1β€”β€”β€”β€”β€”
Total assets7.8r3.25.88.626251112r3.02.4r
Accounts payable1.1r0.90.30.30.20.30.10.30.10.0r
Debt due within a yearβ€”β€”β€”β€”β€”β€”β€”0.22.4β€”
Current liabilities2.2r1.50.71.01.01.21.20.62.60.1r
Lease liabilities (non-current)β€”β€”0.10.20.00.10.1β€”β€”β€”
Total liabilities2.2r1.50.81.11.02.32.92.8r2.60.1r
Retained earningsβˆ’101rβˆ’87βˆ’75βˆ’64βˆ’37βˆ’25βˆ’11βˆ’7.6βˆ’3.9βˆ’2.0r
Shareholders' equity5.6r1.7r5.07.52523r8.09.70.4rβˆ’2.3r
Total liabilities and equity7.8r3.25.88.626251112r3.02.4r
Shares outstanding2.60.1r1.30.8r1614r5.5r5.5r3532r
Cash-flow statement
Share-based compensation0.90.61.18.83.42.70.50.1β€”0.0
Cash from operating activitiesβˆ’11βˆ’11βˆ’8.1βˆ’9.6βˆ’8.7βˆ’3.1βˆ’2.8βˆ’3.7βˆ’1.7βˆ’2.2r
Capital expenditureβ€”βˆ’0.0βˆ’0.0β€”β€”β€”β€”β€”βˆ’0.0βˆ’0.0
Intangible assets boughtβ€”β€”β€”β€”β€”β€”β€”βˆ’0.0rβ€”β€”
Cash from investing activitiesβˆ’0.9βˆ’0.0βˆ’0.0β€”β€”β€”β€”βˆ’0.01.0βˆ’1.0r
Shares issued177.86.36.41017β€”2.9β€”4.3
Cash from financing activities177.76.3βˆ’0.49.8181.72.62.44.3r
Change in cash4.3βˆ’3.5βˆ’1.8βˆ’10.01.115βˆ’1.0βˆ’1.11.81.1r
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K/A10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Sep 30, 2026

Executive pay at Processa Pharmaceuticals, Inc.#

From the pay-versus-performance table of the company's proxy statement. β€œActually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$673 K
George Ng
Other top executives, average
$531 K
the CEO earned 1.3Γ— this
$100 invested is now
$2
Processa Pharmaceuticals, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025George Ng$673 K$565 K$531 K$2
2024George Ng$521 K$288 K$286 K$13
2023George Ng$473 K$429 K$322 K$100

As of Dec 31, 2025

Events at Processa Pharmaceuticals, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 Β· Acquisition or sale completed 1 Β· Directors and officers 4 Β· Material agreement 7 Β· Agreement ended 2 Β· Unregistered share sale 3 Β· Shareholder rights changed 1 Β· Bylaws or fiscal year changed 3 Β· Shareholder vote 8

Processa Pharmaceuticals, Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Directors and officersShareholder vote8-K
Acquisition or sale completedDirectors and officersMaterial agreementAgreement endedUnregistered share saleBylaws or fiscal year changed8-K
Directors and officers8-K
Agreement ended8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Bylaws or fiscal year changedShareholder vote8-K/A
Shareholder vote8-K
Shareholder vote8-K
Shareholder vote8-K
Material agreementUnregistered share sale8-K/A
Delisting notice8-K
Material agreementUnregistered share sale8-K
Shareholder vote8-K
Shareholder vote8-K
Material agreement8-K
Material agreementShareholder vote8-K
Material agreement8-K
Material agreement8-K

As of Nov 4, 2026

Acquisitions and funding#

1 acquisitions, $3 M paid where reported Β· 2 private funding rounds before listing

Businesses it acquired

Acquisitions by Processa Pharmaceuticals, Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
Asset Purchase Agreement2011β€”$3 Mβ€”Annual report

Private share sales Β· funding history

Private share sales of Processa Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2021$10 MPrivate placement after listing$10 to $50 million18equity, optionsSEC
May 2018$3 MPrivate placement after listing$2 to $10 million33equity, optionsSEC
Jul 2013$2 MNo. 2$2 to $10 million51equity, optionsSEC
Aug 2012$2 MNo. 1Under $2 million44equitySEC

How Processa Pharmaceuticals, Inc. compares in Biotechnology

  • Market cap$5 M Β· higher than 6% of 726
  • Revenue growth0.0% Β· higher than 42% of 439
  • Price / book0.9Γ— Β· lower than 80% of 532

Peer comparison Β· Biotechnology

CompanyMarket capP/ENet marginRev. growth
Processa Pharmaceuticals, Inc.πŸ‡ΊπŸ‡Έ$5 Mβ€”β€”0.0%
Novo Nordisk A/SπŸ‡©πŸ‡°$203.2 B13.1Γ—33.1%+10.8%
Vertex Pharmaceuticals IncorporatedπŸ‡ΊπŸ‡Έ$134.3 B33.8Γ—30.7%+8.9%
Moderna, Inc.πŸ‡ΊπŸ‡Έ$90.1 Bβ€”-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.πŸ‡ΊπŸ‡Έ$84.1 B17.5Γ—28.5%+1.0%
Argenx SEπŸ‡³πŸ‡±$52.8 B40.9Γ—31.1%+89.9%
CSL LimitedπŸ‡¦πŸ‡Ί$51.6 Bβ€”-16.4%β€”
Samsung Biologics Co., Ltd.πŸ‡°πŸ‡·$51.5 B40.5Γ—39.2%β€”
UCB SAπŸ‡§πŸ‡ͺ$48.6 B26.3Γ—20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 22, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Processa Pharmaceuticals, Inc.? Verify and update this profile β€” free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Processa Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Processa Pharmaceuticals, Inc.? Suggest a correction